drugset
drugset / Trial / NCT05656274

A Study of the Safety,Tolerability,and Pharmacokinetics of Multiple-Ascending Dose JS1-1-01 in Healty Subjects.

NCT05656274 ↗

Phase 1 Completed 48 enrolled Tasly Pharmaceutical Group Co., Ltd
RandomizedSequentialDouble-blindPrevention

Summary

The purpose of this study is to evaluate the safety，tolerability，and pharmacokinetics of multiple-accending dose of JS1-1-01。

Timeline

Start
2022-11-29
Primary completion
2023-07-24
Completion
2023-07-24

Drugs

EvaluationDrugModalityDoseRoute
Subject JS1-1-01 Unknown 25 mg Oral
Subject JS1-1-01 Unknown 50 mg Oral
Subject JS1-1-01 Unknown 100 mg Oral
Subject JS1-1-01 Unknown 150 mg Oral

Indications

No indication recorded.